{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T09:04:12Z","timestamp":1774343052940,"version":"3.50.1"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Frail patients are considered at relevant risk of complications due to coronavirus disease 2019 (COVID-19) infection and, for this reason, are prioritized candidates for vaccination. As these patients were originally not included in the registration trials, fear related to vaccine adverse events and disease worsening was one of the reasons for vaccine hesitancy. Herein, we report the safety profile of the prospective, multicenter, national VAX4FRAIL study (NCT04848493) to evaluate vaccines in a large trans-disease cohort of patients with solid or hematological malignancies and neurological and rheumatological diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between March 3 and September 2, 2021, 566 patients were evaluable for safety endpoint: 105 received the mRNA-1273 vaccine and 461 the BNT162b2 vaccine. Frail patients were defined per protocol as patients under treatment with hematological malignancies (n = 131), solid tumors (n = 191), immune-rheumatological diseases (n = 86), and neurological diseases (n = 158), including multiple sclerosis and generalized myasthenia. The impact of the vaccination on the health status of patients was assessed through a questionnaire focused on the first week after each vaccine dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The most frequently reported moderate\u2013severe adverse events were pain at the injection site (60.3% after the first dose, 55.4% after the second), fatigue (30.1%\u201341.7%), bone pain (27.4%\u201327.2%), and headache (11.8%\u201318.9%). Risk factors associated with the occurrence of severe symptoms after vaccine administration were identified through a multivariate logistic regression analysis: age was associated with severe fever presentation (younger patients vs. middle-aged vs. older ones), female individuals presented a higher probability of severe pain at the injection site, fatigue, headache, and bone pain; and the mRNA-1237 vaccine was associated with a higher probability of severe pain at the injection site and fever. After the first dose, patients presenting a severe symptom were at a relevant risk of recurrence of the same severe symptom after the second one. Overall, 11 patients (1.9%) after the first dose and 7 (1.2%) after the second one required postponement or suspension of the disease-specific treatment. Finally, two fatal events occurred among our 566 patients. These two events were considered unrelated to the vaccine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study reports that mRNA-COVID-19 vaccination is safe also in frail patients; as expected, side effects were manageable and had a minimum impact on patient care path.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2022.855723","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T08:44:02Z","timestamp":1647506642000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients"],"prefix":"10.3389","volume":"12","author":[{"given":"Maria Teresa","family":"Lupo-Stanghellini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Di Cosimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Costantini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Monti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Mantegazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matilde","family":"Inglese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Apolone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennaro","family":"Ciliberto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto","family":"Baldanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo","family":"Morrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Sinno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Notari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Turola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Silvestris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30442-3","article-title":"COVID-19 Prevalence and Mortality in Patients With Cancer and the Effect of Primary Tumour Subtype and Patient Demographics: A Prospective Cohort Study","volume":"21","author":"Lee","year":"2020","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 Mortality in Patients With Cancer on Chemotherapy or Other Anticancer Treatments: A Prospective Cohort Study","volume":"395","author":"Lee","year":"2020","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117147","article-title":"COVID-19 in Multiple Sclerosis Patients and Risk Factors for Severe Infection","volume":"418","author":"Chaudhry","year":"2020","journal-title":"J Neurol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1001\/jamaneurol.2021.0688","article-title":"Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis","volume":"78","author":"Salter","year":"2021","journal-title":"JAMA Neurol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e002630","DOI":"10.1136\/jitc-2021-002630","article-title":"COVID-19 in Immunocompromised Populations: Implications for Prognosis and Repurposing of Immunotherapies","volume":"9","author":"Goldman","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18105272","article-title":"Willingness to Be Vaccinated Against COVID-19 in Spain Before the Start of Vaccination: A Cross-Sectional Study","volume":"18","author":"Rodr\u00edguez-Blanco","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9070792","article-title":"Acceptance of COVID-19 Vaccination in Cancer Patients in Hong Kong: Approaches to Improve the Vaccination Rate","volume":"9","author":"Chan","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050411","article-title":"Attitudes of Patients With Cancer Towards Vaccinations-Results of Online Survey With Special Focus on the Vaccination Against COVID-19","volume":"9","author":"Brodziak","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-021-01046-w","article-title":"COVID-19 Vaccines for Patients With Cancer: Benefits Likely Outweigh Risks","volume":"14","author":"Hwang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211030647","article-title":"COVID-19 Vaccine Hesitancy in Multiple Sclerosis: A Cross-Sectional Survey","volume":"27","author":"Uhr","year":"2021","journal-title":"Mult Scler"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103163","article-title":"COVID-19 Vaccine Hesitancy in Adults With Multiple Sclerosis in the United States: A Follow Up Survey During the Initial Vaccine Rollout in 2021","volume":"54","author":"Ehde","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-04938-9","article-title":"COVID-19 Vaccine Hesitancy in Patients With Systemic Autoimmune Rheumatic Disease: An Interview-Based Survey","volume":"41","author":"Gaur","year":"2021","journal-title":"Rheumatol Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9060566","article-title":"Global Prevalence and Drivers of Dental Students' COVID-19 Vaccine Hesitancy","volume":"9","author":"Riad","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.770985","article-title":"COVID-19 Vaccine Hesitancy in the United States: A Systematic Review","volume":"9","author":"Yasmin","year":"2021","journal-title":"Front Public Health"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhe.2021.02.025","article-title":"Vaccine Hesitancy in the Era of COVID-19","volume":"194","author":"Troiano","year":"2021","journal-title":"Public Health"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00155-8","article-title":"Short-Term Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients With Cancer Treated With Immune Checkpoint Inhibitors","volume":"22","author":"Waissengrin","year":"2021","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143573","article-title":"COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience","volume":"13","author":"So","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"S2666","DOI":"10.1016\/j.jtct.2021.06.024","article-title":"Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients After Allogeneic HCT or CD19-Based CART Therapy-A Single-Center Prospective Cohort Study","volume":"27","author":"Ram","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and Immunogenicity of One Versus Two Doses of the COVID-19 Vaccine BNT162b2 for Patients With Cancer: Interim Analysis of a Prospective Observational Study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00212-5","article-title":"The Effect of Methotrexate and Targeted Immunosuppression on Humoral and Cellular Immune Responses to the COVID-19 Vaccine BNT162b2: A Cohort Study","volume":"3","author":"Mahil","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-021-01090-6","article-title":"Fifth-Week Immunogenicity and Safety of Anti-SARS-CoV-2 BNT162b2 Vaccine in Patients With Multiple Myeloma and Myeloproliferative Malignancies on Active Treatment: Preliminary Data From a Single Institution","volume":"14","author":"Pimpinelli","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.242","article-title":"Safety and Immunogenicity of a First Dose of SARS-CoV-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients","volume":"1","author":"Chevallier","year":"2021","journal-title":"EJHaem"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00169-1","article-title":"Immunogenicity of the BNT162b2 COVID-19 mRNA Vaccine and Early Clinical Outcomes in Patients With Haematological Malignancies in Lithuania: A National Prospective Cohort Study","volume":"8","author":"Maneikis","year":"2021","journal-title":"Lancet Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15028","article-title":"Safety of the BNT162b2 COVID-19 Vaccine in Multiple Sclerosis (MS): Early Experience From a Tertiary MS Center in Israel","volume":"28","author":"Lotan","year":"2021","journal-title":"Eur J Neurol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211003476","article-title":"COVID-19 Vaccination in Patients With Multiple Sclerosis: What We Have Learnt by February 2021","volume":"27","author":"Achiron","year":"2021","journal-title":"Mult Scler"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103028","article-title":"Experience With the COVID-19 AstraZeneca Vaccination in People With Multiple Sclerosis","volume":"52","author":"Allen-Philbey","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Adult Patients With Autoimmune Inflammatory Rheumatic Diseases and in the General Population: A Multicentre Study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9070730","article-title":"Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines in Rheumatic Diseases: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers Study","volume":"9","author":"Rotondo","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220503","article-title":"Disease Activity and Humoral Response in Patients With Inflammatory Rheumatic Diseases After Two Doses of the Pfizer mRNA Vaccine Against SARS-CoV-2","volume":"80","author":"Braun-Moscovici","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00221-6","article-title":"Tolerance of COVID-19 Vaccination in Patients With Systemic Lupus Erythematosus: The International VACOLUP Study","volume":"3","author":"Felten","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-04917-0","article-title":"Safety of the ChAdOx1 Ncov-19 and the BBV152 Vaccines in 724 Patients With Rheumatic Diseases: A Post-Vaccination Cross-Sectional Survey","volume":"41","author":"Cherian","year":"2021","journal-title":"Rheumatol Int"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220231","article-title":"Safety of the First Dose of mRNA SARS-CoV-2 Vaccines in Patients With Rheumatic and Musculoskeletal Diseases","volume":"19","author":"Connolly","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00181-8","article-title":"Adverse Events After First COVID-19 Vaccination in Patients With Autoimmune Diseases","volume":"3","author":"Boekel","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001814","article-title":"Early Experience of COVID-19 Vaccination in Adults With Systemic Rheumatic Diseases: Results From the COVID-19 Global Rheumatology Alliance Vaccine Survey","volume":"7","author":"Sattui","year":"2021","journal-title":"RMD Open"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.08.078","article-title":"Characterization of Humoral Response to COVID mRNA Vaccines in Multiple Sclerosis Patients on Disease Modifying Therapies","volume":"39","author":"Ali","year":"2021","journal-title":"Vaccine"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.08.035","article-title":"COVID-19 Vaccines in Adult Cancer Patients With Solid Tumours Undergoing Active Treatment: Seropositivity and Safety. A Prospective Observational Study in Italy","volume":"157","author":"Cavanna","year":"2021","journal-title":"Eur J Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100274","article-title":"Reduced Humoral Immune Response After BNT162b2 Coronavirus Disease 2019 Messenger RNA Vaccination in Cancer Patients Under Antineoplastic Treatment","volume":"6","author":"Peeters","year":"2021","journal-title":"ESMO Open"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01542-z","article-title":"Immune Responses to Two and Three Doses of the BNT162b2 mRNA Vaccine in Adults With Solid Tumors","volume":"27","author":"Shroff","year":"2021","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2439","article-title":"Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients With Solid Cancer: A Large Cohort Prospective Study From a Single Institution","volume":"27","author":"Di Noia","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184621","article-title":"Responses to SARS-CoV-2 Vaccination in Patients With Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group","volume":"13","author":"Linardou","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100272","article-title":"A Snapshot of the Immunogenicity, Efficacy and Safety of a Full Course of BNT162b2 Anti-SARS-CoV-2 Vaccine in Cancer Patients Treated With PD-1\/PD-L1 Inhibitors: A Longitudinal Cohort Study","volume":"6","author":"Lasagna","year":"2021","journal-title":"ESMO Open"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.08.007","article-title":"Efficacy and Safety of BNT162b2 Vaccination in Patients With Solid Cancer Receiving Anticancer Therapy - a Single Centre Prospective Study","volume":"157","author":"Shmueli","year":"2021","journal-title":"Eur J Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e212675","DOI":"10.1001\/jamaoncol.2021.2675","article-title":"Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer","volume":"8","author":"Goshen-Lago","year":"2021","journal-title":"JAMA Oncol"},{"key":"B46","doi-asserted-by":"crossref","DOI":"10.55563\/clinexprheumatol\/xj2pqk","article-title":"Safety of BNT162b2 mRNA COVID-19 Vaccine in a Cohort of Elderly, Immunocompromised Patients With Systemic Vasculitis","author":"Delvino","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.704110","article-title":"COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial","volume":"12","author":"Agrati","year":"2021","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12904-016-0095-6","article-title":"Validity, Reliability and Responsiveness to Change of the Italian Palliative Care Outcome Scale: A Multicenter Study of Advanced Cancer Patients","volume":"15","author":"Costantini","year":"2016","journal-title":"BMC Palliat Care"},{"key":"B49","doi-asserted-by":"crossref","DOI":"10.2307\/2529310","article-title":"The Measurement of Observer Agreement for Categorical Data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18157859","article-title":"COVID-19 Vaccines Safety Tracking (CoVaST): Protocol of a Multi-Center Prospective Cohort Study for Active Surveillance of COVID-19 Vaccines\u2019 Side Effects","volume":"18","author":"Riad","year":"2021","journal-title":"Int J Environ Res Public Health"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.855723\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T05:46:37Z","timestamp":1674971197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.855723\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":50,"alternative-id":["10.3389\/fonc.2022.855723"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.855723","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.01.18.22269351","asserted-by":"object"}]},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"article-number":"855723"}}